Latest Antibiotic for Clostridium Difficile Significantly Reduces Recurrence of the Infection by 74% Versus Standard of Care
New data presented at the Federation of Infection Societies Conference (FIS) 2014, demonstrates that first-line use of fidaxomicin reduces recurrence of potentially-fatal Clostridium difficile infection (C. diff.) by 74%, compared to older therapies, vancomycin and metronidazole (10.6% vs. 2.8%). The study looked at all patients, and in the group of patients given fidaxomicin first-line there was a lower 28-day all-cause mortality compared with the other treatments (7.6% in those receiving fidaxomicin vs. 23.3% receiving vancomycin or metronidazole). Based on the results observed in this evaluation and the current levels of C. diff. found in the UK, first-line use of fidaxomicin could prevent more than 2000 recurrences of infection every year taking into account the current expected recurrences with vancomycin.
Commenting on the findings, Dr Simon Goldenberg, Consultant Microbiologist and Infection Control Doctor, Guy’s and St Thomas’ NHS Foundation Trust, said: “Today’s results show a genuine step change in the treatment of C. diff. It is gratifying to see this treatment performing in the real world as well it did in the clinical trial setting. From my experience of using fidaxomicin, it has the potential to benefit both patients and the NHS by preventing repeat infections and ultimately saving valuable NHS resources. In the last 10 years we have drastically reduced rates of C. diff. in the UK through stringent infection prevention measures; but now it’s time for a new approach to overall management of C. diff.”
Recurrence is a major challenge in CDI treatment, with up to 25% of all patients receiving vancomycin or metronidazole experiencing a return of infection within 4 weeks of initial therapy. This risk increases to 40% following a first recurrence, and continues to increase exponentially with each recurrence thereafter. In the real world evaluation, where patients suffered a first recurrence of CDI, 23.8% of those not receiving fidaxomicin had a second recurrence. This compared to only 6.7% of all patients receiving treatment with fidaxomicin.
Prof. Mark Wilcox, Consultant Microbiologist, Leeds Teaching Hospitals commented: “Preventing recurrence is a key goal of CDI management. Recurrence of CDI should be seen as a therapeutic failure. Today’s results demonstrating the capacity of fidaxomicin to markedly reduce recurrences in routine clinical practice are very encouraging, as are reductions in associated mortality.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance